Perimeter Medical Imaging AI Announces Symposium and Its Participation at ASBrS 2023

Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS) from April 26-30, 2023, in Boston, MA.

Rhea-AI Summary

Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS) from April 26-30, 2023, in Boston, MA. The company will host an educational symposium titled "ACT IN THE MOMENT: OCT adds real-time clarity on margin status," featuring prominent breast surgeons who will share their experiences utilizing the Perimeter S-Series Optical Coherence Tomography (OCT) technology. This device provides real-time imaging to assist surgeons during procedures. Perimeter will also offer live demonstrations at Booth #923, showcasing the OCT system's capabilities in visualizing tissue margins at a cellular level. The event underscores Perimeter's commitment to advancing breast cancer surgery technology.

Positive

• Participation in a key industry conference could enhance visibility and credibility.
• Live demonstrations of the S-Series OCT may lead to increased interest and potential sales.
• Engagement with leading breast surgeons suggests a focused marketing strategy.

Negative

• No immediate financial data or metrics presented to gauge impact.

Argus Session date unavailable

-0.74% session move Open Argus

Details

News Market Reaction – PYNKF

The recorded move for PYNKF in the trading session of this news was -0.74%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Demos of Perimeter S-Series OCT at Perimeter's Booth at the 24^th Annual Meeting of the American Society of Breast Surgeons

TORONTO and DALLAS, April 27, 2023 /PRNewswire/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced that it will host an educational symposium featuring the Perimeter S-Series OCT technology at the upcoming annual meeting of the American Society of Breast Surgeons (ASBrS) taking place April 26-30, 2023 at the John B. Hynes Veterans Memorial Convention Center in Boston, MA.

#ASBRS23 - 24^th Annual Meeting of the American Society of Breast Surgeons 

Educational Symposium

Title:	"ACT IN THE MOMENT: OCT adds real-time clarity on margin status"
Presenters:	Beth Anglin, MD, FACS, Breast Surgeon, Plano, TX
	Michele Carpenter, MD, FACS, Breast Surgeon, Orange, CA
	Beth DuPree, MD, FACS, ABOIM, Breast Surgeon, Sedona, AZ (moderator)
Date/Time:	Friday, April 28, 6:15-7:45 a.m. ET
Learn More:	Session details and registration for attendees can be found here. For those not attending in person, a recording of the presentation will be available following the conference.

 

Steve Sapot, Perimeter's Chief Commercial Officer, stated, "ASBrS is a key conference where breast surgeons meet to share the latest research and education to advance the practice of breast surgery. We are excited to be joined for the symposium by leading breast surgeons, Drs. Beth Anglin, Michele Carpenter, and Beth Dupree, who will share their experiences using S-Series OCT in their ORs to help personalize clinical decisions for each patient at the point of care. In addition, we look forward to connecting ASBrS attendees at Booth #923 in the exhibit hall, where we will be featuring live demos on the S-Series OCT device showing its ability to visualize microscopic features at a 2mm depth – ideal to aid surgeons with real-time clarity on margin status."

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter's intention to participate in the American Society of Breast Surgeons (ASBrS) conference; Perimeter's expected marketing and sales activities; and the expected details regarding Perimeter's ongoing clinical trials, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2022, which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-symposium-and-its-participation-at-asbrs-2023-301809609.html

SOURCE Perimeter Medical Imaging AI, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the Perimeter Medical Imaging AI symposium at ASBrS 2023 about?

The symposium, titled 'ACT IN THE MOMENT: OCT adds real-time clarity on margin status,' will feature presentations by leading breast surgeons on the use of Perimeter's S-Series OCT technology.

When is the Perimeter Medical Imaging AI symposium scheduled?

The symposium is set for Friday, April 28, 2023, from 6:15-7:45 a.m. ET.

Where can I find more information about the Perimeter S-Series OCT technology?

More information about the S-Series OCT technology can be found on Perimeter's official website.

What is the significance of ASBrS 2023 for Perimeter Medical Imaging AI?

ASBrS 2023 is a prominent conference for breast surgeons, providing Perimeter an opportunity to showcase its innovative technology and network with industry professionals.

What are the ticker symbols for Perimeter Medical Imaging AI?

Perimeter Medical Imaging AI trades under the ticker symbols TSXV: PINK and OTC: PYNKF.